Glucagon-like peptide-1 receptor agonists

Abstract

Get full access to this article

View all access options for this article.

References

Mozaffarian

Agarwal

Aggarwal

, et al. (2025) Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 33(8): 1475–1503. DOI: 10.1002/oby.24336.

Nauck

Tuttle

Tschöp

, et al. (2026) Glucagon-like receptor agonists and next-generation incretin-based medications: Metabolic, cardiovascular, and renal benefits. The Lancet 407(10531): 892–908. DOI: 10.1016/S0140-6736(25)02105-1.

NICE (2024) Guidance: Tirzepatide for managing overweight and obesity. Available at: www.nice.org.uk/guidance/ta1026 (accessed 12 March 2026).

Tyler

(2026) Beyond the prescription: A holistic GP approach to obesity and weight loss medications. InnovAiT. Epub ahead of print 11 February 2016. DOI: 10.1177/17557380261420769.